CN1433413A - 新的噁唑烷酮衍生物及其制备方法 - Google Patents

新的噁唑烷酮衍生物及其制备方法 Download PDF

Info

Publication number
CN1433413A
CN1433413A CN01810697A CN01810697A CN1433413A CN 1433413 A CN1433413 A CN 1433413A CN 01810697 A CN01810697 A CN 01810697A CN 01810697 A CN01810697 A CN 01810697A CN 1433413 A CN1433413 A CN 1433413A
Authority
CN
China
Prior art keywords
oxo
oxazolidinyl
fluorophenyl
methylacetamide
pyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN01810697A
Other languages
English (en)
Chinese (zh)
Inventor
李在杰
任元彬
曹宗焕
崔成鹤
李钟镇
朴商国
李太镐
金东九
成铉贞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
East-Asia Pharmaceutical Co Ltd
Original Assignee
East-Asia Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020000030896A external-priority patent/KR100674096B1/ko
Priority claimed from KR1020000056035A external-priority patent/KR100731469B1/ko
Priority claimed from KR1020010011691A external-priority patent/KR100713170B1/ko
Application filed by East-Asia Pharmaceutical Co Ltd filed Critical East-Asia Pharmaceutical Co Ltd
Publication of CN1433413A publication Critical patent/CN1433413A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
CN01810697A 2000-06-05 2001-05-18 新的噁唑烷酮衍生物及其制备方法 Pending CN1433413A (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
KR1020000030896A KR100674096B1 (ko) 2000-06-05 2000-06-05 피리미딘 고리를 포함하는 신규 옥사졸리디논 유도체와그의 제조방법
KR20000030895 2000-06-05
KR2000/30896 2000-06-05
KR2000/30895 2000-06-05
KR2000/56035 2000-09-23
KR1020000056035A KR100731469B1 (ko) 2000-06-05 2000-09-23 피리딘 고리를 포함하는 옥사졸리디논 유도체 및 그의제조방법
KR2001/11691 2001-03-07
KR1020010011691A KR100713170B1 (ko) 2001-03-07 2001-03-07 헤테로고리 또는 헤테로아로마틱 고리가 치환된 피리딘고리를 포함하는 옥사졸리디논 유도체 및 그의 제조방법

Publications (1)

Publication Number Publication Date
CN1433413A true CN1433413A (zh) 2003-07-30

Family

ID=27483456

Family Applications (1)

Application Number Title Priority Date Filing Date
CN01810697A Pending CN1433413A (zh) 2000-06-05 2001-05-18 新的噁唑烷酮衍生物及其制备方法

Country Status (11)

Country Link
US (1) US6689779B2 (enExample)
EP (1) EP1289984A4 (enExample)
JP (1) JP2003535860A (enExample)
CN (1) CN1433413A (enExample)
AU (1) AU5889701A (enExample)
BR (1) BR0111280A (enExample)
CA (1) CA2411859A1 (enExample)
HU (1) HUP0301562A2 (enExample)
MX (1) MXPA02012045A (enExample)
NZ (1) NZ522990A (enExample)
WO (1) WO2001094342A1 (enExample)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101619061A (zh) * 2009-08-11 2010-01-06 沈阳药科大学 氰基吡啶基取代的噁唑烷酮类化合物
CN101560209B (zh) * 2008-04-15 2011-09-14 沈阳中海药业有限公司 含有嘧啶的噁唑烷酮类化合物及其制备方法
CN102260277A (zh) * 2010-05-24 2011-11-30 中国科学院上海药物研究所 新型苯并噁嗪噁唑烷酮类化合物及其制备方法和用途
CN103030635A (zh) * 2011-09-29 2013-04-10 山东轩竹医药科技有限公司 联芳基杂环取代的噁唑烷酮抗菌药
WO2013182070A1 (zh) * 2012-06-08 2013-12-12 四川贝力克生物技术有限责任公司 一种用于预防或治疗分支杆菌疾病的药物
CN103476772A (zh) * 2011-03-30 2013-12-25 乐高化工生物科学株式会社 新型噁唑烷酮衍生物及包含该噁唑烷酮衍生物的药物组合物
CN102171207B (zh) * 2008-09-24 2014-04-16 乐高化工生物科学株式会社 带有环状偕胺肟或环状脒腙的噁唑烷酮衍生物及其药物组合物
TWI471322B (zh) * 2008-10-27 2015-02-01 Mitsubishi Tanabe Pharma Corp 新穎醯胺衍生物及其作為醫藥之用途
CN102516238B (zh) * 2003-12-18 2016-08-03 东亚St株式会社 噁唑烷酮衍生物
CN106068263A (zh) * 2014-02-21 2016-11-02 弗洛斯特生物科技有限公司 用于治疗癌症和增殖性疾病的抗有丝分裂酰胺
CN106083994A (zh) * 2016-04-18 2016-11-09 南京曼杰生物科技有限公司 取代的噁唑烷酮水溶性衍生物及其应用
CN113321683A (zh) * 2021-06-07 2021-08-31 南开大学 含有p–n键的化合物及制备方法
CN118164975A (zh) * 2024-05-14 2024-06-11 中国医学科学院医药生物技术研究所 一种季铵盐类噁唑烷酮衍生物及其可药用盐、制备方法和应用

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9928568D0 (en) 1999-12-03 2000-02-02 Zeneca Ltd Chemical compounds
GB0009803D0 (en) 2000-04-25 2000-06-07 Astrazeneca Ab Chemical compounds
KR100674096B1 (ko) 2000-06-05 2007-01-26 동아제약주식회사 피리미딘 고리를 포함하는 신규 옥사졸리디논 유도체와그의 제조방법
KR100731469B1 (ko) * 2000-06-05 2007-06-21 동아제약주식회사 피리딘 고리를 포함하는 옥사졸리디논 유도체 및 그의제조방법
US6861433B2 (en) * 2000-12-15 2005-03-01 Pharmacia & Upjohn Company Oxazolidinone photoaffinity probes
EP1367053A4 (en) * 2001-02-27 2005-08-03 Kaneka Corp PROCESS FOR THE PRODUCTION OF OPTICALLY ACTIVE N-ARYL-1-AMINO-2-PROPANOL DERIVATIVES
EP1385834B1 (en) * 2001-04-17 2005-09-14 Merck & Co., Inc. Bicyclo[3,1,0]hexane containing oxazolidinone antibiotic and derivatives thereof
US7396847B2 (en) * 2001-09-11 2008-07-08 Astrazeneca Ab Oxazolidinone and/or isoxazoline as antibacterial agents
FR2829766A1 (fr) * 2001-09-14 2003-03-21 Lipha Derives d'oxamates comportant un heterocycle azote diversement substitue
WO2004014897A1 (en) * 2002-08-12 2004-02-19 Pharmacia & Upjohn Company Llc N-aryl-2-oxazolidinones and their derivatives
KR100856745B1 (ko) 2002-10-18 2008-09-04 동아제약주식회사 헤테로 고리 및 헤테로아로마틱 고리가 치환 또는 융합된피리딘을 포함하는 옥사졸리디논 유도체 및 그의 제조방법
CA2507628A1 (en) * 2002-11-28 2004-06-10 Astrazeneca Ab Oxazolidinones as antibacterial agents
JP2006508192A (ja) * 2002-11-28 2006-03-09 アストラゼネカ アクチボラグ 抗細菌薬としてのオキサゾリジノンおよび／またはイソオキサゾリン誘導体
GB0227701D0 (en) * 2002-11-28 2003-01-08 Astrazeneca Ab Chemical compounds
GB0229522D0 (en) * 2002-12-19 2003-01-22 Astrazeneca Ab Chemical compounds
GB0229526D0 (en) * 2002-12-19 2003-01-22 Astrazeneca Ab Chemical compounds
GB0229521D0 (en) * 2002-12-19 2003-01-22 Astrazeneca Ab Chemical compounds
GB0229518D0 (en) * 2002-12-19 2003-01-22 Astrazeneca Ab Chemical compounds
TW200500360A (en) 2003-03-01 2005-01-01 Astrazeneca Ab Hydroxymethyl compounds
US20060270680A1 (en) * 2003-06-03 2006-11-30 Goldberg Joel A Sulfonamide compounds and methods of making and using the same
US8324398B2 (en) 2003-06-03 2012-12-04 Rib-X Pharmaceuticals, Inc. Process for the synthesis of biaryl oxazolidinones
ES2393292T3 (es) * 2003-06-03 2012-12-20 Rib-X Pharmaceuticals, Inc. Compuestos heterocíclicos de biarilo y métodos de obtención y uso de los mismos
NZ544237A (en) * 2003-07-02 2008-09-26 Merck & Co Inc Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereof
UA88448C2 (ru) * 2003-07-02 2009-10-26 Мерк Энд Ко., Инк. Оксазолидиноновые антибиотики с замещенной циклопропильной группой и их производные
US20070185132A1 (en) * 2003-07-02 2007-08-09 Yasumichi Fukuda Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereo
WO2005005422A1 (en) * 2003-07-02 2005-01-20 Merck & Co., Inc. Oxazolidinone antibiotics and derivatives thereof
US20060247286A1 (en) * 2003-07-02 2006-11-02 Milton Hammond Oxazolidinone antibiotics and derivatives thereof
JP2007500707A (ja) * 2003-07-29 2007-01-18 リブ−エックス ファーマシューティカルズ，インコーポレイテッド ビアリールヘテロ環状のアミン、アミドおよび硫黄−含有化合物、並びに該化合物の製造方法および使用方法
US7129259B2 (en) 2003-12-17 2006-10-31 Rib-X Pharmaceuticals, Inc. Halogenated biaryl heterocyclic compounds and methods of making and using the same
BRPI0511526A (pt) * 2004-05-25 2007-12-26 Astrazeneca Ab composto, pró-droga, método para a produção de um efeito antibacteriano em um animal de sangue quente, uso de um composto, composição farmacêutica, e, processo para a preparação de um composto
CA2567929A1 (en) * 2004-05-25 2005-12-08 Astrazeneca Ab 3- {4- (pyridin-3-yl) phenyl} -5- (1h-1, 2, 3-triazol-1-ylmethyl) -1, 3-oxazolidin-2-ones as antibacterial agents
EP1778653A1 (en) * 2004-07-28 2007-05-02 Rib-X Pharmaceuticals, Inc. Biaryl heterocyclic compounds and methods of making and using the same
WO2006018682A2 (en) * 2004-08-11 2006-02-23 Ranbaxy Laboratories Limited Oxazolidinone derivatives as antimicrobials
EP1799677A1 (en) * 2004-10-08 2007-06-27 Ranbaxy Laboratories Limited Oxazolidinone derivatives as antimicrobials
US7592335B2 (en) 2005-04-15 2009-09-22 Ranbaxy Laboratories Limited Oxazolidinone derivatives as antimicrobials
JP5534497B2 (ja) 2005-06-08 2014-07-02 メリンタ セラピューティクス，インコーポレイテッド トリアゾール類の合成方法
EP1912980A2 (en) * 2005-06-20 2008-04-23 Wockhardt Limited Oxazolidinones bearing antimicrobial activity composition and methods of preparation
CN100406455C (zh) * 2006-02-20 2008-07-30 中国科学院上海药物研究所 含三氮唑基的噁唑烷酮类化合物及其制备方法和用途
EP2183241B1 (en) * 2007-05-03 2012-12-19 Pfizer Limited 2-pyridine carboxamide derivatives as sodium channel modulators
EP2072514A1 (en) * 2007-12-17 2009-06-24 Ferrer Internacional, S.A. 1(2)H-tetrazol-5-yl-phenyl-oxazolidinones as antibacterial agents
KR20110022089A (ko) 2008-06-27 2011-03-04 노파르티스 아게 유기 화합물
CA2738671C (en) * 2008-10-10 2018-05-01 Trius Therapeutics, Inc. Methods for preparing oxazolidinones and compositions containing them
CN102224151A (zh) 2008-11-20 2011-10-19 万能药生物有限公司 新的抗微生物剂
AP2987A (en) 2009-02-03 2014-09-30 Trius Therapeutics Crystalline form of (R)-3-(-4(2-(2-methyltetrazol-5-YL)pyridin-5-YL)-3-fluorophenyl)-5-hydroxymethyloxazolidin-2-one dihydrogen phosphate
US8580767B2 (en) * 2009-05-28 2013-11-12 Trius Therapeutics, Inc. Oxazolidinone containing dimer compounds, compositions and methods to make and use
US8906913B2 (en) 2009-06-26 2014-12-09 Panacea Biotec Limited Azabicyclohexanes
EA022765B1 (ru) 2009-10-13 2016-02-29 Мелинта Терапьютикс, Инк. Фармацевтическая композиция
WO2012033952A1 (en) * 2010-09-10 2012-03-15 Micurx Pharmaceuticals, Inc. 3 - phenyl- 2 -oxo- 1, 3 -oxazolidines for treatment of bacterial infections
MX2013003101A (es) 2010-09-17 2013-09-26 Purdue Pharma Lp Compuestos de piridina y sus usos.
NZ610638A (en) 2010-11-24 2015-05-29 Melinta Therapeutics Inc Pharmaceutical compositions comprising radezolid
PL2970205T3 (pl) 2013-03-14 2019-10-31 Tolero Pharmaceuticals Inc Inhibitory jak2 i alk2 oraz sposoby ich zastosowania
UY35464A (es) 2013-03-15 2014-10-31 Araxes Pharma Llc Inhibidores covalentes de kras g12c.
WO2014143659A1 (en) 2013-03-15 2014-09-18 Araxes Pharma Llc Irreversible covalent inhibitors of the gtpase k-ras g12c
HK1219690A1 (zh) 2013-03-15 2017-04-13 Melinta Subsidiary Corp. 利用抗生素来治疗超重和肥胖患者感染的方法
JO3805B1 (ar) 2013-10-10 2021-01-31 Araxes Pharma Llc مثبطات كراس جي12سي
US9573910B2 (en) 2013-11-08 2017-02-21 Lee Pharma Limited Oxazolidinone antibacterial compound
KR101561964B1 (ko) 2013-11-15 2015-10-20 한국과학기술연구원 옥사졸리디논 화합물 및 이를 포함하는 c형 간염 예방 또는 치료용 약학 조성물
JO3556B1 (ar) 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
ES2826443T3 (es) * 2014-09-25 2021-05-18 Araxes Pharma Llc Inhibidores de proteínas mutantes KRAS G12C
WO2016049568A1 (en) 2014-09-25 2016-03-31 Araxes Pharma Llc Methods and compositions for inhibition of ras
AR102666A1 (es) 2014-11-14 2017-03-15 Melinta Therapeutics Inc Método para tratar, prevenir, o reducir el riesgo de infección de la piel, formulación y uso
AU2016245864C1 (en) 2015-04-10 2021-09-09 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
MX2017013275A (es) 2015-04-15 2018-01-26 Araxes Pharma Llc Inhibidores triciclicos fusionados de kras y metodos de uso de los mismos.
US10144724B2 (en) 2015-07-22 2018-12-04 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
WO2017058807A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
US10647703B2 (en) 2015-09-28 2020-05-12 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10858343B2 (en) 2015-09-28 2020-12-08 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
WO2017058792A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
WO2017058805A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
EP3356339A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
WO2017058915A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
WO2017070256A2 (en) 2015-10-19 2017-04-27 Araxes Pharma Llc Method for screening inhibitors of ras
WO2017066964A1 (en) * 2015-10-22 2017-04-27 Merck Sharp & Dohme Corp. Oxazolidinone compounds and methods of use thereof as antibacterial agents
CA3005089A1 (en) 2015-11-16 2017-05-26 Araxes Pharma Llc 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
WO2017100546A1 (en) 2015-12-09 2017-06-15 Araxes Pharma Llc Methods for preparation of quinazoline derivatives
US10822312B2 (en) 2016-03-30 2020-11-03 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
EP3519402A1 (en) 2016-09-29 2019-08-07 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
WO2018068017A1 (en) 2016-10-07 2018-04-12 Araxes Pharma Llc Heterocyclic compounds as inhibitors of ras and methods of use thereof
EP3573964A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC Benzothiophene and benzothiazole compounds and methods of use thereof
US11279689B2 (en) 2017-01-26 2022-03-22 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer
WO2018140514A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
WO2018140512A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
JP7327802B2 (ja) 2017-01-26 2023-08-16 アラクセス ファーマ エルエルシー 縮合ヘテロ－ヘテロ二環式化合物およびその使用方法
JP2020521741A (ja) 2017-05-25 2020-07-27 アラクセス ファーマ エルエルシー がんの処置のための化合物およびその使用の方法
CN110831933A (zh) 2017-05-25 2020-02-21 亚瑞克西斯制药公司 喹唑啉衍生物作为突变kras、hras或nras的调节剂
CA3063440A1 (en) 2017-05-25 2018-11-29 Araxes Pharma Llc Covalent inhibitors of kras
WO2019118311A1 (en) 2017-12-13 2019-06-20 Merck Sharp & Dohme Corp. Pharmaceutical compositions of tedizolid phosphate
KR20210003780A (ko) 2018-04-05 2021-01-12 스미토모 다이니폰 파마 온콜로지, 인크. Axl 키나제 억제제 및 그의 용도
EP3826684A4 (en) 2018-07-26 2022-04-06 Sumitomo Dainippon Pharma Oncology, Inc. METHODS OF TREATMENT OF DISEASES ASSOCIATED WITH ABNORMAL ACVR1 EXPRESSION AND ACVR1 INHIBITORS FOR USE IN THE SAME
CN112584833A (zh) 2018-08-01 2021-03-30 亚瑞克西斯制药公司 杂环螺化合物及其用于治疗癌症的使用方法
US12365656B2 (en) 2019-01-18 2025-07-22 Merck Sharp & Dohme Llc Oxazolidinone compounds and methods of use thereof as antibacterial agents
WO2021184339A1 (en) 2020-03-20 2021-09-23 Merck Sharp & Dohme Corp. Oxazolidinone compound and methods of use thereof as an antibacterial agent
WO2021258013A1 (en) 2020-06-18 2021-12-23 Akagera Medicines, Inc. Oxazolidinone compounds, liposome compositions comprising oxazolidinone compounds and methods of use thereof
KR20230124927A (ko) 2020-11-25 2023-08-28 아카제라 메디신즈, 인크. 핵산 전달을 위한 지질 나노입자, 및 관련 사용 방법
CN114213352B (zh) * 2021-12-09 2023-05-05 苏州汉德创宏生化科技有限公司 一种1-氧代-1-(2-氧代恶唑烷-3-基)丙-2-基4-甲基苯磺酸酯的制备方法
US12064479B2 (en) 2022-05-25 2024-08-20 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids and methods of use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5130316A (en) * 1988-07-29 1992-07-14 Du Pont Merck Pharmaceutical Company Aminomethyloxooxazlidinyl arylbenzene derivatives useful as antibacterial agents
EP0610265B1 (en) 1991-11-01 1996-12-27 PHARMACIA & UPJOHN COMPANY Substituted aryl- and heteroarylphenyloxazolidinones useful as antibacterial agents
SK283420B6 (sk) 1992-05-08 2003-07-01 Pharmacia & Upjohn Company Antimikrobiálne oxazolidinóny obsahujúce substituované diazínové skupiny
NZ274966A (en) 1993-11-22 1998-01-26 Upjohn Co Substituted-hydroxyacetyl piperazine phenyl oxazolidinone derivatives, use in pharmaceutical compositions

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102516238B (zh) * 2003-12-18 2016-08-03 东亚St株式会社 噁唑烷酮衍生物
CN101560209B (zh) * 2008-04-15 2011-09-14 沈阳中海药业有限公司 含有嘧啶的噁唑烷酮类化合物及其制备方法
CN102171207B (zh) * 2008-09-24 2014-04-16 乐高化工生物科学株式会社 带有环状偕胺肟或环状脒腙的噁唑烷酮衍生物及其药物组合物
TWI471322B (zh) * 2008-10-27 2015-02-01 Mitsubishi Tanabe Pharma Corp 新穎醯胺衍生物及其作為醫藥之用途
CN101619061B (zh) * 2009-08-11 2014-12-17 沈阳药科大学 氰基吡啶基取代的噁唑烷酮类化合物
CN101619061A (zh) * 2009-08-11 2010-01-06 沈阳药科大学 氰基吡啶基取代的噁唑烷酮类化合物
CN102260277B (zh) * 2010-05-24 2013-07-24 中国科学院上海药物研究所 新型苯并噁嗪噁唑烷酮类化合物及其制备方法和用途
US8507481B2 (en) 2010-05-24 2013-08-13 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Benzoxazine oxazolidinone compounds, preparation methods and uses thereof
CN102260277A (zh) * 2010-05-24 2011-11-30 中国科学院上海药物研究所 新型苯并噁嗪噁唑烷酮类化合物及其制备方法和用途
WO2011147259A1 (zh) * 2010-05-24 2011-12-01 中国科学院上海药物研究所 新型苯并噁嗪噁唑烷酮类化合物及其制备方法和用途
CN103476772A (zh) * 2011-03-30 2013-12-25 乐高化工生物科学株式会社 新型噁唑烷酮衍生物及包含该噁唑烷酮衍生物的药物组合物
CN103476772B (zh) * 2011-03-30 2016-03-30 乐高化工生物科学株式会社 噁唑烷酮衍生物及包含该噁唑烷酮衍生物的药物组合物
CN103030635B (zh) * 2011-09-29 2015-11-25 山东轩竹医药科技有限公司 联芳基杂环取代的噁唑烷酮抗菌药
CN103030635A (zh) * 2011-09-29 2013-04-10 山东轩竹医药科技有限公司 联芳基杂环取代的噁唑烷酮抗菌药
CN104364240A (zh) * 2012-06-08 2015-02-18 四川贝力克生物技术有限责任公司 一种用于预防或治疗分支杆菌疾病的药物
WO2013182070A1 (zh) * 2012-06-08 2013-12-12 四川贝力克生物技术有限责任公司 一种用于预防或治疗分支杆菌疾病的药物
CN106068263A (zh) * 2014-02-21 2016-11-02 弗洛斯特生物科技有限公司 用于治疗癌症和增殖性疾病的抗有丝分裂酰胺
CN106083994A (zh) * 2016-04-18 2016-11-09 南京曼杰生物科技有限公司 取代的噁唑烷酮水溶性衍生物及其应用
CN106083994B (zh) * 2016-04-18 2019-12-06 南京曼杰生物科技有限公司 取代的噁唑烷酮水溶性衍生物及其应用
CN113321683A (zh) * 2021-06-07 2021-08-31 南开大学 含有p–n键的化合物及制备方法
CN118164975A (zh) * 2024-05-14 2024-06-11 中国医学科学院医药生物技术研究所 一种季铵盐类噁唑烷酮衍生物及其可药用盐、制备方法和应用
CN118164975B (zh) * 2024-05-14 2024-08-09 中国医学科学院医药生物技术研究所 一种季铵盐类噁唑烷酮衍生物及其可药用盐、制备方法和应用

Also Published As

Publication number Publication date
CA2411859A1 (en) 2001-12-13
NZ522990A (en) 2003-08-29
US20030166620A1 (en) 2003-09-04
BR0111280A (pt) 2003-06-10
EP1289984A4 (en) 2004-11-24
WO2001094342A1 (en) 2001-12-13
JP2003535860A (ja) 2003-12-02
EP1289984A1 (en) 2003-03-12
US6689779B2 (en) 2004-02-10
MXPA02012045A (es) 2003-10-15
AU5889701A (en) 2001-12-17
HUP0301562A2 (hu) 2003-12-29

Similar Documents

Publication Publication Date Title
CN1433413A (zh) 新的噁唑烷酮衍生物及其制备方法
CN1293076C (zh) 过氧化物酶体增殖剂应答性受体δ的活化剂
CN1221548C (zh) 含有砜亚氨基官能团的噁唑烷酮
CN1310907C (zh) 杂环化合物和以其为有效成分的抗肿瘤药
CN1122803A (zh) 苯并噁唑基-和苯并噻唑基噁唑烷酮类化合物
CN1656083A (zh) 具有抗菌活性的新的杂环化合物、它们的制备方法和含有它们的药物组合物
CN1106806A (zh) 粘结受体拮抗剂iii
CN1447808A (zh) 作为杀菌剂的噁唑烷酮衍生物
CN1894242A (zh) 新型噁唑烷酮衍生物
CN1312800A (zh) 治疗用的联芳基衍生物
CN1432015A (zh) 可用作细胞增殖抑制剂的被1,1－二氧代异噻唑烷取代的吲唑
CN1138037A (zh) 粘连受体拮抗剂
CN1069640C (zh) 噁唑烷酮衍生物,其制备方法及含它们的药物组合物
CN101035781A (zh) 2－吗啉基－4－嘧啶酮化合物
CN1520412A (zh) 作为抗菌剂的新噁唑烷酮衍生物
CN101048397A (zh) 作为τ蛋白激酶1抑制剂的6－（吡啶基）－4－嘧啶酮衍生物
CN1157376C (zh) 芳基哌啶子基丙醇和芳基哌嗪子基丙醇衍生物和含有它们的药物
CN1204889C (zh) 粘附受体拮抗剂
CN1668308A (zh) 作为抗菌剂的噁唑烷酮衍生物
CN1145066A (zh) 氨基芪唑衍生物和药
CN1291979C (zh) 咪唑化合物及其作为腺苷脱氨酶抑制剂的用途
CN1169797C (zh) 抗病毒的嘧啶二酮衍生物及其制备方法
CN1318051A (zh) 带有芳香族含氮杂环的新型脲衍生物
CN1922190A (zh) 3－吡啶甲基头胞化合物
CN1202096C (zh) 2－氨基噻唑啉衍生物及其作为no－合酶抑制剂的用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1054748

Country of ref document: HK